Home Tags Seattle Genetics

Tag: Seattle Genetics

Phase I/II Clinical Trial of Vadastuximab Talirine Initiated in Patients with...

Earlier today Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer,  confirmed that...

First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

First Study to Evaluate Brentuximab Vedotin as Front-line Treatment Confirms Effective,...

A study published in the September 16, 2015 online edition of Blood, the Journal of the American Society of Hematology (ASH), reports that brentuximab...

Phase II Trial Evaluates Brentuximab Vedotin in Systemic Lupus Erythematosus

A new phase II clinical trial designed to evaluate the safety and efficacy of brentuximab vedotin (Adcetris®; Seattle Genetics) in systemic lupus erythematosus also known...

Unum Therapeutics Joins Forces with Seattle Genetics in the Development of...

Seattle Genetics and Unum Therapeutics have entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer...

FDA Grants Priority Review for Brentuximab Vedotin in the Post-Transplant Consolidation...

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA setting...

Supplemental BLA for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at...

Based on positive data from the Phase III AETHERA trial (SGN35-005; NCT01100502) of brentuximab vedotin (Adcetris®; Seattle Genetics, Inc/Takeda Oncology) as consolidation therapy immediately following...

Immuno-Oncology SEA-CD40 Moves Into Phase I Clinical Trial for Advanced Solid...

Earlier today, Seattle Genetics Inc, announced the initiation of a new Phase I clinical trial of SEA-CD40, which utilizes the company's proprietary Sugar-Engineered Antibody technology...

SGN-CD33A Demonstrates Encouraging Antitumor Activity in Acute Myeloid Leukemia

To-date, the treatment of acute myeloid leukemia or  AML remains general unsatisfactory.  Both the medical and scientific communities are looking for urgently needed novel...

Four-Year Survival Data from Brentuximab Vedotin Trial in Relapsed or Refractory...

Four-year overall survival (OS) data from the brentuximab vedotin (Adcetris®; Seattle Genetics) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell...